David Lawson, MD
- Professor of Hematology & Medical Oncology, Emory University School of Medicine
Sponsored Research Projects
- A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K
- BRF115532 - COMBI-AD: A phase III randomized double blind study of dabrafenib
- CA209067 -A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy combination
- Proleukin® Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Affiliated Units
- Emory University School of Medicine